A merger agreement between Shanghai Henlius Biotech (HKG:2696) and Shanghai Fosun Pharmaceutical (Group) (SHA:600196, HKG:2196) has been terminated, a Wednesday Hong Kong bourse filing said.
Under the contract signed in June 2024, Fosun Pharma had agreed to acquire the shares it didn't already own in Henlius Biotech.
While the special resolution regarding the proposal was approved by the requisite majority at the firm's extraordinary general meeting, it was rejected at the H shareholders' class meeting.
Despite the deal falling through, Shanghai Fosun Pharmaceutical, which holds a 59.56% stake in Shanghai Henlius Biotech, will retain its controlling position in the latter.
Shares of Fosun Pharma were up over 1% in Hong Kong in recent trade, while Henlius Biotech fell over 4%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.